Prostate Cancer Biomarker Panel for Biopsy Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for screening and monitoring prostate cancer are plagued by low sensitivity and specificity, leading to high false-positive rates and unnecessary invasive biopsies, which result in complications and increased healthcare costs.
Innovation Solution
The use of specific groups of biomarkers and a method to detect their levels in biological samples, such as peripheral blood, sera, plasma, or urine, to characterize, diagnose, prognosticate, stratify, and monitor the progression or recurrence of prostate cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If digital rectal examination, imaging tests, and PSA measurement are used for prostate cancer screening, then screening coverage is achieved, but false-positive rate increases and diagnostic accuracy decreases
Solution Approach 1:
The invention segments the diagnostic process by introducing a multi-step workflow: initial PSA screening followed by risk stratification using additional biomarkers (hGF, PTHrP, PTH, DKK1, SFRP1, SFRP2, BMP7) before biopsy decision. This segmentation allows differentiation between low-risk and high-risk cases, reducing false positives while maintaining screening coverage.
Solution Approach 2:
The invention introduces intermediary biomarkers (hGF, PTHrP, PTH, DKK1, SFRP1, SFRP2, BMP7) that mediate between the initial PSA measurement and the final biopsy decision. These intermediaries provide additional diagnostic information to refine risk assessment and reduce unnecessary biopsies.
2Reliability
If invasive needle biopsies are performed to confirm elevated PSA levels, then diagnostic confirmation is achieved, but patient complications and healthcare costs increase
Solution Approach 1:
The invention performs preliminary risk stratification using multiple biomarkers before proceeding to invasive biopsy. By assessing the combined levels of PSA, hGF, PTHrP, PTH, DKK1, SFRP1, SFRP2, and BMP7, the system identifies low-risk cases that can avoid biopsy altogether, preventing complications before they occur.
Solution Approach 2:
The invention changes the diagnostic parameters from relying solely on PSA levels to using a composite biomarker profile. This parameter change enables more accurate risk stratification, allowing clinicians to avoid unnecessary biopsies in low-risk patients while maintaining high diagnostic confirmation for true cancer cases.
3Productivity
If current screening methods are used, then prostate cancer detection is performed, but unnecessary biopsies and healthcare costs increase
Solution Approach 1:
The invention replaces the mechanical invasive biopsy system with a biochemical assessment system using multiple biomarkers. By substituting the mechanical biopsy procedure with a laboratory-based biomarker analysis, the system reduces the number of unnecessary biopsies while maintaining or improving detection accuracy.
Solution Approach 2:
The invention creates a universal biomarker panel that serves multiple functions: initial risk assessment, triage for biopsy decision-making, and potential monitoring tool. This multi-functional approach improves screening efficiency by consolidating multiple diagnostic functions into a single comprehensive test panel.
Data Source
AI summary
Provided is a method of accurate and sensitive characterization and prognosis of prostate cancer in a subject. The method includes obtaining a biological sample from the subject and determining the level of identified biomarkers.